Clinical trial
A Phase II/III, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection
NCT05115019 is registered in ClinicalTrials.gov with PT. Innovative Pharma Solutions as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II/III, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection
- Lead sponsor
- PT. Innovative Pharma Solutions
- Phase
- Phase 2/3
- Overall status
- Withdrawn
- Start date
- December 31, 2021
- Completion date
- April 30, 2022
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.